Medpace Q2 revenue rises 14.2% to $603.3 million; diluted EPS $3.10 vs $2.75
Medpace reported second-quarter 2025 revenue of $603.3 million, up 14.2% from a year earlier, and GAAP diluted earnings of $3.10 per share, up from $2.75. Net income margin fell to 15.0% from 16.7%, and backlog declined 1.8% to $2,873.6 million, while the company repurchased $518.5 million of its stock in the quarter and issued full-year 2025 guidance.
Key points
- Q2 2025 revenue $603.3 million, up 14.2% from $528.1 million; GAAP net income $90.3 million, or $3.10 per diluted share, vs. $2.75 a year earlier
- Full-year 2025 guidance: revenue $2.420 billion to $2.520 billion; GAAP net income $405.0 million to $428.0 million; diluted EPS $13.76 to $14.53
- Q2 share repurchases of 1,754,264 shares for $518.5 million; $826.3 million remained under the program as of June 30, 2025
- Amendment No. 9 to the PNC Bank unsecured credit facility, dated July 17, 2025, sets line-of-credit borrowing of up to $10 million
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 21, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.